JP Morgan Chase’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-85,000
Closed -$8.24M – 6064
2019
Q3
$8.24M Buy
+85,000
New +$8.51M ﹤0.01% 2288
2019
Q2
– Sell
-12,600
Closed -$1.44M – 6151
2019
Q1
$1.44M Buy
+12,600
New +$926K ﹤0.01% 3572
2018
Q4
– Sell
-30,000
Closed -$1.64M – 6068
2018
Q3
$1.64M Hold
30,000
– – ﹤0.01% 3601
2018
Q2
$2.48M Sell
30,000
-22,600
-43% -$1.74M ﹤0.01% 3250
2018
Q1
$3.5M Buy
52,600
+30,000
+133% +$1.73M ﹤0.01% 2864
2017
Q4
$1.16M Buy
+22,600
New +$1.62M ﹤0.01% 3642

JP Morgan Chase's ONCE Position: Q4 2019 in Review

JP Morgan Chase sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 499,936 shares — an estimated $48.5M sold.

JP Morgan Chase first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $191M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • JP Morgan Chase reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • JP Morgan Chase sold 499,936 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $48.5M.
  • JP Morgan Chase first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • JP Morgan Chase's Spark Therapeutics, Inc. Common Stock position peaked at $191M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.